[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jamia Millia Islamia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633862","scn9a-gene-expression-and-inflammatory-cytokines-100633862",false,"NCT07532200","SCN9A Gene Expression and Inflammatory Cytokines","Association of SCN9A (Nav1.7) Gene Expression and Inflammatory Cytokines (IL-6, TNF-α, IL-1β) With the Success of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: A Prospective Case-Control Study","Gene Expressio","Inclusion Criteria:\n\n* Patients aged 18-60 years\n* Systemically healthy individuals (ASA I or II)\n* Presence of a mandibular first or second molar diagnosed with symptomatic irreversible pulpitis\n* Vital tooth confirmed by positive response to pulp sensibility tests (cold test\u002FEPT)\n* Moderate to severe preoperative pain (Heft-Parker VAS)\n* Patients requiring endodontic treatment under inferior alveolar nerve block\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Patients who have taken analgesics, anti-inflammatory drugs, or antibiotics within the last 48 hours\n* Presence of systemic diseases affecting pain perception or inflammation (e.g., diabetes, neuropathic disorders)\n* Pregnant or lactating women\n* Teeth with periapical abscess, swelling, or sinus tract\n* Non-vital teeth or teeth with previous endodontic treatment\n* Patients with known allergy to local anesthetic agents\n* Patients with limited mouth opening or anatomical conditions affecting IANB administration\n* Inability to understand pain assessment scales or comply with study protocol",true,"ALL","18 Years","50 Years",{"count":22,"type":23},100,"ESTIMATED","1 Month","OBSERVATIONAL","Voltage-gated sodium channels, especially Nav1.7 encoded by the SCN9A gene, are key regulators of nociceptive transmission. Upregulation of SCN9A has been associated with increased neuronal excitability and heightened pain perception. In parallel, inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) are known to sensitize peripheral nociceptors and reduce the efficacy of local anesthetics by modifying tissue environment and ion channel activity. However, the combined influence of SCN9A expression and inflammatory cytokines on anesthetic success in SIP has not been fully elucidated.\n\nThis prospective case-control study aims to evaluate the association between SCN9A gene expression and inflammatory cytokine levels with the clinical success of IANB in patients with SIP affecting mandibular molars. Approximately 90-100 patients will be recruited and categorized into two groups based on anesthetic outcome: successful anesthesia and failed anesthesia. All patients will receive a standardized IANB using 2% lidocaine with 1:100,000 epinephrine. Anesthetic success will be determined based on the absence of pain during access cavity preparation and instrumentation.\n\nFollowing access and pulp extirpation, pulpal tissue samples will be collected. SCN9A gene expression will be assessed using quantitative real-time polymerase chain reaction (RT-qPCR), with relative expression calculated using the 2\\^-ΔΔCt method. Inflammatory cytokine levels (IL-6, TNF-α, IL-1β) will be quantified using enzyme-linked immunosorbent assay (ELISA).\n\nThe primary outcome will be the difference in SCN9A expression between failed and successful anesthesia groups. Secondary outcomes will include comparison of cytokine levels and evaluation of correlations between SCN9A expression and inflammatory markers. Statistical analysis will include group comparisons, correlation analysis, logistic regression, and receiver operating characteristic (ROC) curve analysis to assess the predictive value of these biomarkers.",[28],"Pulpitis - Irreversible",[30,31,32,33,34],"Symptomatic irreversible pulpitis","Inferior alveolar nerve block","Gene expression","RT-qPCR","Inflammatory cytokines","RECRUITING","2026-05-27",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":39},"2026-04-10",{"date":43,"type":23},"2026-09-30",{"name":45,"class":46},"Jamia Millia Islamia","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100616509","effect-of-menstrual-phase-on-the-anesthetic-efficacy-100616509","NCT07306533","Effect of Menstrual Phase on the Anesthetic Efficacy","Effect of Menstrual Phase on the Anesthetic Efficacy of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars","Inclusion Criteria\n\n* Female patients aged 20-40 years.\n* Regular menstrual cycles (28 ± 3 days).\n* Diagnosed with symptomatic irreversible pulpitis in mandibular molars.\n* Indicated for root canal therapy.\n* Willing to provide informed consent. Exclusion Criteria\n* Use of oral contraceptives or hormonal therapy.\n* Irregular menstrual cycles.\n* Pregnancy or lactation.\n* Systemic disease affecting pain perception (e.g., diabetes, neuropathies).\n* Recent use of analgesics or sedatives (within 24 hours).\n* Allergy to local anesthetics.","FEMALE","45 Years",{"count":58,"type":23},150,"INTERVENTIONAL",[61],"NA","The goal of this observational prospective clinical study is to learn whether the menstrual phase influences the anesthetic efficacy of inferior alveolar nerve block (IANB) in female patients aged 20-40 years with symptomatic irreversible pulpitis in mandibular molars. The main questions it aims to answer are:\n\nDoes the success rate of IANB vary across different phases of the menstrual cycle?\n\nAre certain menstrual phases associated with a higher likelihood of anesthetic failure during endodontic access preparation?\n\nResearchers will compare five menstrual phase groups (menstrual, follicular, ovulatory, luteal, and premenstrual) to see if hormonal fluctuations affect anesthetic success.\n\nParticipants will:\n\nReceive a standardized inferior alveolar nerve block using 2% lidocaine with 1:80,000 epinephrine\n\nUndergo cold testing and access cavity preparation to assess anesthetic success\n\nHave intraoperative pain recorded using the Heft-Parker Visual Analog Scale (HPVAS), with menstrual phase information recorded confidentially and blinded to the treating clinician",[28],[65,66,67],"IANB","pulpitis","anesthesia","2025-12-25",{"date":70,"type":39},"2025-12-29",{"date":72,"type":39},"2025-09-11",{"date":74,"type":23},"2026-03-10",{"name":45,"class":46},""]